Esperion Therapeutics Revenue, Profits - ESPR Annual Income Statement

Add to My Stocks
$45.57 $1.69 (3.58%) ESPR stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the Esperion Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 impacts the ESPR stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Esperion Therapeutics profit and loss statement for 2017 total to $168.97M. This line item shows that the operating expenses has increased compared with last year. Also check: Esperion Therapeutics assets and Esperion Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Esperion Therapeutics Revenues or Net Sales
-------
Cost Of Goods Sold (COGS)-------
Esperion Therapeutics Gross Profit
-------
Research & Development Expense147.6M57.86M29.8M25.3M16.01M7.99M7.8M
Selling General & Admin Expense21.37M18.28M20.23M10.92M6.74M2.2M2.35M
Income Before Depreciation Depletion Amortization-168.98M-76.15M-50.04M-36.22M-22.75M-10.2M-10.16M
Depreciation Depletion Amortization-------
Non Operating Income2.19M1.54M---2.39M-0.05M-0.07M
Interest Expense-----1.48M-
Esperion Therapeutics Pretax Income
-166.98M-74.97M-49.78M-36.37M-26.08M-11.74M-10.81M
Provision for Income Taxes-------
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-166.98M-74.97M-49.78M-36.37M-26.08M-11.74M-10.81M
Extraordinary Items & Discontinued Operations-------
Esperion Therapeutics Profit/ Loss (Net Income)
-166.98M-74.97M-49.78M-36.37M-26.08M-11.74M-10.81M
Average Shares used to compute Diluted EPS23.93M22.55M22.02M16.37M7.89M3.76M-
Average Shares used to compute Basic EPS23.93M22.55M22.02M16.37M7.89M3.76M-
Income Before Nonrecurring Items-166.99M-74.98M-49.78M-36.38M-23.42M-11.74M-
Income from Nonrecurring Items-----2.59M--
Esperion Therapeutics Earnings Per Share Basic Net
-6.98-3.33-2.26-2.22-3.31-3.13-
Esperion Therapeutics Earnings Per Share Diluted Net
-6.98-3.33-2.26-2.22-3.31-3.13-
EPS Diluted Before Nonrecurring Items-6.98-3.33-2.26-2.22-2.98-3.13-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Esperion Therapeutics stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that ESPR stock has a topline or revenue of $- for 2017 as per this Esperion Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-166.98M for ESPR stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the ESPR income statement, one can check the Esperion Therapeutics historical stock prices to check how the price has moved with time.

Esperion Therapeutics Income Statement - Key Financial Ratios